Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (18)

2023

  1. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86

2022

  1. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308

2021

  1. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  2. Pd-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high pd-l1 expression: A network meta-analysis

    Journal of Clinical Medicine, Vol. 10, Núm. 7

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

2017

  1. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226

2015

  1. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial

    JAMA Oncology, Vol. 1, Núm. 2, pp. 149-157

2012

  1. Biological markers of cisplatin resistance in advanced testicular germ cell tumours

    Clinical and Translational Oncology, Vol. 14, Núm. 6, pp. 452-457

  2. Recommendations for the optimal management of early and advanced urothelial carcinoma

    Cancer Treatment Reviews, Vol. 38, Núm. 5, pp. 431-441

2010

  1. Treatment of cancer with oral drugs: A position statement by the Spanish Society of Medical Oncology (SEOM)

    Annals of Oncology

2009

  1. Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma

    European Journal of Cancer, Vol. 45, Núm. 5, pp. 732-735

2007

  1. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 25, Núm. 19, pp. 2747-2754

  2. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy

    Annals of Oncology, Vol. 18, Núm. 3, pp. 522-528

  3. How could pharmacogenomics help improve patient survival?

    Lung Cancer, Vol. 57, Núm. SUPPL. 2

  4. Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors

    Future Oncology, Vol. 3, Núm. 3, pp. 277-283

2005

  1. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial

    Clinical Cancer Research, Vol. 11, Núm. 2 I, pp. 690-696

  2. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer

    Annals of Oncology, Vol. 16, Núm. 4, pp. 597-601

2003

  1. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

    Annals of Oncology, Vol. 14, Núm. 6, pp. 867-872